San Diego-based Viking Therapeutics marked itself as a serious competitor in the weight loss drug current market in February soon after revealing promising data from a mid-phase trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when supplied for a weekly injection and in March the company unveiled